ClinicalTrials.gg
Active, not recruitingNCT04931342BOUQUETUpdated Sep 10, 2026

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

A Phase 2 interventional study of Ipatasertib and Cobimetinib in Ovarian Cancer, sponsored by Hoffmann-La Roche. Active, not recruiting at 41 sites in 13 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
176
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Ovarian Neoplasms by Hoffmann-La Roche — none open to participants now, 3 under way, none of them phase 3. Ovarian Neoplasms · Hoffmann-La Roche.

Enrollment
10th of 30
176 · median 100
Started
2021
with 1 other
Phase 2
12 of 35
none open now
Registered
33rd of 35
by date

Among the 35 studies in Ovarian Neoplasms by Hoffmann-La Roche, this one is the 10th largest by enrollment of the 30 interventional ones that give a count, is one of 2 that started in 2021, is one of 12 in phase 2, and was the 33rd registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

None of the 35 studies in Ovarian Neoplasms by Hoffmann-La Roche is open now. The open studies under Ovarian Neoplasms, anywhere →

Who these studies take

Of the 602 Ovarian Neoplasms studies recruiting now, 439 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 35 studies in Ovarian Neoplasms by Hoffmann-La Roche as a file.
02

Study summary

This study will evaluate the efficacy and safety of multiple biomarker-selected treatments in patients with persistent or recurrent rare epithelial ovarian, fallopian tube, or primary peritoneal tumors. Enrollment will take place in two phases: a preliminary phase followed by a potential expansion phase.

03

Conditions studied

  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Persistent or recurrent EOC that meets the following criteria: confirmed non-high-grade serous, non-high-grade endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer, including but not limited to low-grade serous ovarian carcinoma, clear cell carcinoma, mucinous carcinoma, carcinosarcoma, undifferentiated carcinoma, seromucinous carcinoma, malignant Brenner tumors, Grades 1 or 2 endometrioid carcinoma, mesonephric-like adenocarcinoma and small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). Disease that is not amenable to curative surgery
  • (at least one target lesion) according to v1.1
  • Previous treatment with one to four , at least one of which was platinum-based. Hormonal therapy does not count as a line of therapy.
  • Platinum-resistant disease, defined as disease progression during or within 6 months of last platinum therapy, with the following exception: Participants with primary platinum- disease are excluded.
  • Submission of a representative tumor specimen that is suitable for next-generation sequencing (NGS) testing and estrogen receptor immunohistochemistry (ER IHC) to determine treatment arm assignment and for central pathology review.
  • Submission of the local pathology report and, if available, any associated stained slides that supported the local diagnosis of the histology (to be used for central pathology review)
  • (ECOG) Performance Status of 0 or 1
  • Adequate hematologic and end-organ function
  • For women of : agreement to remain abstinent or use , and agreement to refrain from donating eggs (if applicable)
  • In addition to the general inclusion criteria above, participants must meet all of the arm-specific inclusion criteria for the respective arm

General Exclusion Criteria:

  • Pregnant or breastfeeding, or intending to become pregnant or breastfeed during the study
  • Primary platinum-refractory disease, defined as progression during or within 4 weeks after the last dose of the first-line platinum treatment
  • Histologic diagnosis of high-grade serous or high-grade endometrioid ovarian, fallopian tube, or primary peritoneal cancer
  • Current diagnosis of solely borderline epithelial ovarian tumor
  • Current diagnosis of non-epithelial ovarian tumors
  • Current diagnosis of synchronous primary endometrial cancer
  • Prior history of primary endometrial cancer, with the following exception: a prior diagnosis of primary endometrial cancer is permitted if it meets all of the following conditions: Stage IA, no lymphovascular invasion, International Federation of Gynecology and Obstetrics Grade 1 or 2, not a high-grade subtype.
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures
  • Symptomatic, untreated, or actively progressing
  • Severe infection within 4 weeks prior to initiation of study treatment
  • Treatment with chemotherapy, radiotherapy, antibody therapy or other immunotherapy, gene therapy, vaccine therapy, or therapy within 28 days prior to initiation of study treatment
  • Treatment with hormonal therapy within 14 days prior to initiation of study treatment
  • In addition to the general exclusion criteria above, participants can not meet any of the arm-specific exclusion criteria for the respective arm
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
176 participants (actual)

Study arms

  • Experimental
    Ipatasertib + Paclitaxel (PIK3CA/AKT1/PTEN-altered tumors)

    Participants in the Ipatasertib + Paclitaxel arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.

    Drug: Ipatasertib · Drug: Paclitaxel

  • Experimental
    Cobimetinib (BRAF/NRAS/KRAS/NF1-altered tumors)

    Participants in the Cobimetinib arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.

    Drug: Cobimetinib

  • Experimental
    Trastuzumab Emtansine (ERBB2-amplified/mutant tumors)

    Participants in the Trastuzumab Emtansine arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.

    Drug: Trastuzumab Emtansine

  • Experimental
    Atezolizumab + Bevacizumab (Non-matched)

    Participants in the Atezolizumab + Bevacizumab arm will receive treatment until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.

    Drug: Atezolizumab · Drug: Bevacizumab

  • Experimental
    Giredestrant + Abemaciclib (ER+ tumors)

    Participants in the Giredestrant + Abemaciclib arm will receive treatment until unacceptable toxicity or disease progression as determined by the investigator according to RECIST v1.1.

    Drug: Giredestrant · Drug: Abemaciclib · Drug: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists

  • Experimental
    Inavolisib + Palbociclib (PIK3CA-altered tumors)

    Participants in the Inavolisib + Palbociclib arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.

    Drug: Inavolisib · Drug: Palbociclib

  • Experimental
    Inavolisib + Palbociclib + Letrozole (ER+ and PIK3CA-altered tumors)

    Participants in the Inavolisib + Palbociclib + Letrozole arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.

    Drug: Inavolisib · Drug: Palbociclib · Drug: Letrozole · Drug: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists

  • Experimental
    Inavolisib + Olaparib (Non-matched)

    Participants in the Inavolisib + Olaparib arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.

    Drug: Inavolisib · Drug: Olaparib

  • Experimental
    Inavolisib + Giredestrant (ER+ and PIK3CA-altered tumors)

    Participants in the Inavolisib + Giredestrant arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.

    Drug: Giredestrant · Drug: Inavolisib

  • Experimental
    Inavolisib + Bevacizumab (PIK3CA-altered tumors)

    Participants in the Inavolisib + Bevacizumab arm will receive treatment until unacceptable toxicity or disease progression per RECIST v1.1.

    Drug: Bevacizumab · Drug: Inavolisib

  • Experimental
    Atezolizumab + Bevacizumab + Cyclophosphamide (Non-matched)

    Participants in the Atezolizumab + Bevacizumab + Cyclophosphamide arm will receive treatment until unacceptable toxicity or loss of clinical benefit as determined by the investigator after an integrated assessment of radiographic and biochemical data, local biopsy results (if available), and clinical status.

    Drug: Atezolizumab · Drug: Bevacizumab · Drug: Cyclophosphamide

Interventions

  • Ipatasertib will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length = 28 days)

    Also known as: RO5532961

  • Cobimetinib will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length=28 days)

    Also known as: RO5514041

  • Trastuzumab Emtansine will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)

    Also known as: RO5304020

  • Atezolizumab will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)

    Also known as: RO5541267, Tecentriq

  • Bevacizumab will be administered intravenously on Day 1 of each cycle. (Cycle length=21 days)

    Also known as: RO4876646, Avastin

  • Paclitaxel will be administered intravenously on Days 1, 8, and 15 of each cycle. (Cycle length=28 days)

  • Giredestrant will be administered by mouth once a day on Days 1-28 of each cycle (Cycle length=28 days)

  • Abemaciclib will be administered by mouth twice a day during each 28-day cycle

  • Inavolisib will be administered by mouth once a day on Days 1-28 of each 28-day cycle

  • Palbociclib will be administered by mouth once a day on Days 1-21 of each 28-day cycle

  • Letrozole will be administered by mouth once a day on Days 1-28 of each 28-day cycle

  • Olaparib will be administered by mouth twice a day on Days 1-28 of each 28-day cycle

  • LHRH agonists are required beginning at least 2 weeks prior to initiation of study treatment for premenopausal or perimenopausal women. Acceptable agents include goserelin or leuprolide; triptorelin is also acceptable. Monthly injections of LHRH agonist are preferred.

  • Cyclophosphamide will be administered by mouth once a day on Days 1-21 of each cycle. (Cycle length = 21 days)

  • Inavolisib will be administered by mouth once a day on Days 1-21 of each 21-day cycle

06

What researchers measure

Primary outcomes

  1. Confirmed Objective Response Rate (ORR)

    Confirmed ORR is defined as the proportion of participants with a confirmed complete response (CR) or partial response (PR) (demonstrated on two consecutive occasions \>=4 weeks apart), as determined by the investigator according to RECIST v1.1.

    Time frame: Up to approximately 5 years

Secondary outcomes

  1. Duration of Response (DOR)

    DOR is defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1.

    Time frame: Up to approximately 5 years

  2. Disease Contral Rate (DCR)

    DCR is defined as the proportion of participants with a confirmed CR or PR, or stable disease maintained for at least 16 weeks, as determined by the investigator according to RECIST v1.1.

    Time frame: Up to approximately 5 years

  3. Progression Free Survival (PFS)

    PFS after start of treatment is defined as the time from start of treatment to the first occurrence of disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1.

    Time frame: Up to approximately 5 years

  4. 6-Month PFS Rate

    6-month PFS rate is defined as the proportion of participants who remained alive and progression-free at 6 months after start of treatment, as determined by the investigator according to RECIST v1.1.

    Time frame: Up to 6 month

  5. Overall Survival (OS)

    OS after start of treatment is defined as the time from start of treatment to death from any cause.

    Time frame: Up to approximately 5 years

  6. Confirmed ORR as Determined by IRC (Independent Review Committee)

    Confirmed ORR, as determined by the IRC according to RECIST v1.1.

    Time frame: Up to approximately 5 years

  7. DOR as Determined by IRC

    DOR, as determined by the IRC according to RECIST v1.1

    Time frame: Up to approximately 5 years

  8. DCR as Determined by IRC

    DCR, as determined by the IRC according to RECIST v1.1

    Time frame: Up to approximately 5 years

  9. PFS as Determined by IRC

    PFS, as determined by the IRC according to RECIST v1.1

    Time frame: Up to approximately 5 years

  10. Percentage of Participants With Adverse Events

    Percentage of participants with adverse events.

    Time frame: Up to approximately 5 years

07

Study locations

41 sites
08

References and documents

Publications

  • Ray-Coquard I, Ledermann J, DeFazio A, Okamoto A, Gershenson D. Controversies in the organization and structure of management for rare tumors. Int J Gynecol Cancer. 2025 Mar;35(3):101669. doi: 10.1016/j.ijgc.2025.101669. Epub 2025 Jan 29. PubMed 40022843 ↗

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Feb 2028, 76 months after the start.

Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's planned 76 months is above that.

Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2021
First posted
Jun 18, 2021
StartActual
Oct 7, 2021
Primary completionEst.
Feb 28, 2028
CompletionEst.
May 30, 2028
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04931342
Lead sponsor
Hoffmann-La Roche
Collaborators
GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Responsible party
Sponsor
First posted
Jun 18, 2021
Start date
Oct 7, 2021
Primary completion
Feb 28, 2028 (estimated)
Completion
May 30, 2028 (estimated)
Last update
Sep 10, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ipatasertib · Cobimetinib · Ado-Trastuzumab Emtansine · Atezolizumab · Bevacizumab · Paclitaxel · Giredestrant · Inavolisib · Olaparib · Gonadotropin-Releasing Hormone · Cyclophosphamide

Start the discussion